Overview

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Zhujiang Hospital
Treatments:
Cisplatin
Doxorubicin
Fluorouracil
Leucovorin
Oxaliplatin
Raltitrexed